Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer
Oslo, Norway, 23 March 2020 Nordic Nanovector ASA (OSE: NANO) announces that Dr Dominic Smethurst has been appointed Interim Chief Medical Officer with immediate effect. Dr Smethurst replaces Dr Lisa Rojkjaer, MD, who after a handover period will leave Nordic Nanovector to pursue other career opportunities. Dr Smethurst is an experienced drug development physician having led complex global clinical trials within oncology. Previously, Dr Smethurst was the Group Medical Director of Tusk Therapeutics, where he played a key role in the development of this private immuno-oncology company